Fig. 3: Possible algorithm for controlling blood pressure in diabetic patients with microalbuminuria. [This algorithm is based on the opinions and practice.

Slides:



Advertisements
Similar presentations
Preventing Strokes One at a Time Acute Interventions and Management 2009.
Advertisements

Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema Effect of renin-angiotensin system blockade on calcium.
JNC 8 Guidelines….
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.
10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
Clinical Management of Chronic Stable Angina. Anti-ischemic strategies in stable CAD Medical therapyPCICABG Initial therapy Recurrent ischemia TMREECPSCS.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
High-dose ARB monotherapy versus ARB/CCB combination on cardiovascular events in Japanese elderly high-risk hypertensive patients. The OSCAR trial Ogawa.
CCB in Management of Hypertension in Older Persons Presented by Mona Ahmed sherif Marwa Shaaban Shimaa Adel Ahmed Salma Sadek Alia khalid.
February 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
Wald DS, et al. Am J Med 2009;122: Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:
Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.
Blood Pressure and Lipid Trials: Rationale, Importance and Design
Hypertension In The Stroke Patient
Hypertension JNC VIII Guidelines.
Copyright © 2015 American Medical Association. All rights reserved.
Copyright © 2005 American Medical Association. All rights reserved.
Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.
Evidence-based treatment algorithm, including clinical trials published through A, B, and C are levels of evidence defined as follows—Level of Evidence:
Subclinical organ damage Treatment LVH
Trends in Medication Choices for Hypertension in the Elderly
Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.
WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,
Mean BP from initial visit to four years
These slides highlight an educational report from a satellite symposium presented at the Annual Scientific Meeting of the Canadian Society of Internal.
Volume 7, Issue 9, Pages (September 2010)
Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene?  Sumeet Gupta, MPharm, PhD,
Nat. Rev. Nephrol. doi: /nrneph
Prevalence of statin and beta-blocker use by clinical presentation
Thinking Beyond New Clinical Guidelines: Update in Hypertension
Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors
Figure 5 Risk factor control in the intensive treatment group
Step Care Therapy for Hypertension in Diabetic Patients
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.
Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus  George L. Bakris, MD  Mayo Clinic.
Hypertension management in high risk type II diabetes with CKD: Insights from recent trials with a focus on albuminuria. A case based discussion  Matthew.
Volume 81, Issue 7, Pages (April 2012)
Fig. 2. Evidence-based medication prescriptions
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Chapter 32 Assessment and Management of Patients With Hypertension
by Ali Albasri, Suman Prinjha, Richard J McManus, and James P Sheppard
by Ali Albasri, Suman Prinjha, Richard J McManus, and James P Sheppard
The future of renoprotection: Frustration and promises
Managing Blood Pressure
Pharmacological Treatment of Hypertension Update 2012
Volume 67, Pages S52-S54 (January 2005)
Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.
Adjusted ORs of AF within 30 days after bereavement with specific characteristics versus non-bereaved with the same characteristics. * *The vertical dashed.
Volume 73, Issue 5, Pages (March 2008)
KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline
Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)
Study protocol. Study protocol. Fourteen patients had research renal biopsies, and 17 patients with macroalbuminuria had renal biopsies for clinical reasons.
Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)
(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.
Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.
Risk of venous thromboembolism by ABO blood type, factor V Leiden R506Q and prothrombin G20210A mutations among individuals in the Copenhagen General.
Number of antihypertensive agents prescribed for known nephropaths in phases I and II (▪), with blood pressure recordings falling outside guidelines, compared.
An updated general approach for achieving BP goals in people with diabetes. An updated general approach for achieving BP goals in people with diabetes.
Schematic of medications used to treat calcium channel blocker (CCB) poisoning, shown at the interface of a blood vessel and cardiac myocyte. Schematic.
Pathway to initial antihypertensive therapy in patients with diabetes
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.
Fig. 1: Ampule of vitamin K
HR for mortality in ischemic heart disease.
Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.
HR for myocardial infarction.
Copyright Notice You are authorized to use these slides subject to the following terms, conditions and exceptions: They are to be used solely for personal,
Hazard ratios for associations between incident hepatitis C virus infection and prescribed dosage of opioid agonist treatment, categorized according to.
Presentation transcript:

Fig. 3: Possible algorithm for controlling blood pressure in diabetic patients with microalbuminuria. [This algorithm is based on the opinions and practice of the authors.] CCB = long-acting calcium-channel blocker. *On the basis of results of recent clinic... Fig. 3: Possible algorithm for controlling blood pressure in diabetic patients with microalbuminuria. [This algorithm is based on the opinions and practice of the authors.] CCB = long-acting calcium-channel blocker. *On the basis of results of recent clinical trials, start with an ARB40 or ACE inhibitor.15 †Possible agents to add are a long-acting dihydropyridine CCB44,47 and a β-blocker if necessary; another possibility instead of these agents is a nondihydropyridine CCB, with no β-blocker, particularly if the patient's heart rate is greater than 80 beats/min.48 Sheldon W. Tobe et al. CMAJ 2002;167:499-503 ©2002 by Canadian Medical Association